Author: Elliott, Brian P; Buchek, Gregory M; Koroscil, Matthew T
Title: Characteristics, Treatment, and Outcomes of Patients With Severe or Life-threatening COVID-19 at a Military Treatment Facility—A Descriptive Cohort Study Cord-id: 4l097a0f Document date: 2021_2_12
ID: 4l097a0f
Snippet: INTRODUCTION: The treatment of severe and life-threatening COVID-19 is a rapidly evolving practice. The purpose of our study was to describe the characteristics and outcomes of patients with severe or life-threatening COVID-19 who present to a Military Treatment Facility (MTF) with an emphasis on addressing institutional adaptations to rapidly changing medical evidence. MATERIALS AND METHODS: A single-center retrospective study conducted on a prospectively maintained cohort. The MTF is a 52-bed
Document: INTRODUCTION: The treatment of severe and life-threatening COVID-19 is a rapidly evolving practice. The purpose of our study was to describe the characteristics and outcomes of patients with severe or life-threatening COVID-19 who present to a Military Treatment Facility (MTF) with an emphasis on addressing institutional adaptations to rapidly changing medical evidence. MATERIALS AND METHODS: A single-center retrospective study conducted on a prospectively maintained cohort. The MTF is a 52-bed hospital within an urban setting. Patients were included in the cohort if they had laboratory-confirmed severe or life-threatening COVID-19 with positive SARS-CoV-2 reverse transcription polymerase chain reaction. Severe disease was defined as dyspnea, respiratory frequency ≥30/min, blood oxygen saturation ≤93% on ambient air, partial pressure of arterial oxygen to fraction of inspired oxygen ratio <300, or lung infiltrates involving >50% of lung fields within 24-48 hours. Life-threatening COVID-19 was defined as respiratory failure, septic shock, or multiple organ dysfunction. The cohort included patients admitted from June 1 through November 13. Data were collected retrospectively via chart review by a resident physician. RESULTS: In total, our MTF saw 14 cases of severe or life-threatening COVID-19 from June 1 to November 13. Patients had a median age of 70.5 years, with 7% being active duty personnel, 21% dependents, and 71% retired military members. The median time to dexamethasone, remdesivir, and convalescent plasma administration was 4.7, 6.3, and 11.2 hours, respectively. The 28-day in-hospital mortality was 0%. CONCLUSIONS: Patients who present to an MTF with severe or life-threatening COVID-19 are largely retirees, with only a small fraction comprising active duty personnel. The institution of order sets and early consultation can help facilitate prompt patient care for COVID-19.
Search related documents:
Co phrase search for related documents- acute respiratory distress syndrome and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- acute respiratory distress syndrome and liver function renal function: 1
- acute respiratory distress syndrome and liver renal: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute respiratory distress syndrome and liver renal function: 1, 2, 3
- acute respiratory distress syndrome and lung field: 1, 2, 3, 4, 5, 6, 7, 8
- acute respiratory distress syndrome and lung infiltrate: 1, 2
- acute respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- liver function and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- liver function renal function and lymphocyte count: 1, 2, 3, 4, 5
- liver renal and lung field: 1
- liver renal and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- liver renal function and lymphocyte count: 1, 2, 3, 4, 5, 6, 7
- lung field and lymphocyte count: 1
Co phrase search for related documents, hyperlinks ordered by date